The prevalence of somatic FOXO3 aberrations is 41%, 9%, and 0.5% in breast cancer, prostate cancer, and CRCs in humans, it has been implicated in liver and brain tumors in mice [39] and is a negative regulator of Ras/MAPK [40]. The gene discussed is FOXO3; the disease is prostate carcinoma.